In summary, our findings highlight the discernible changes in metabolite profiles induced by TRPML1 inhibition using ML-SI1, offering insights into the diverse metabolic pathways affecting KRAS-mutant pancreatic cancer cells. Here, MCOLN1 is linked to familial pancreatic carcinoma.